Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Nonalcoholic Steatohepatitis Market - An Emerging Worldwide Industry

|Includes: Meridian Resource Corp. (TMR)

A new market research report by Transparency Market Research, titled "Nonalcoholic Steatohepatitis (NYSEARCA:NASH) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023," helps in the analysis of key trends prevalent in the market for nonalcoholic steatohepatitis. The study also comprises a review of the chief factors inhibiting and fuelling the growth of the market, thus helping stakeholders in gaining an in-depth understanding of the nonalcoholic steatohepatitis market.

The study also includes data gained through the Porter's five forces model and thus helps in gaining insights into the key threats posed by the emerging entrants as well as the bargaining powers of both buyers and suppliers. Moving further, the study also includes the major strategies adopted by the prime players dominant in the market, along with detailing the key mergers and acquisitions, product launches, and agreements and collaborations seen in the market. In addition, the study also entails SWOT analysis as well as distinctive graphics on the major market segments.

As per the report, nonalcoholic steatohepatitis (NASH) is a kind of non-alcoholic fatty liver disease (NAFLD) involving a hepatocyte injury seen in the form of fibrosis, hepatic steatosis, and inflammation. The report states that the prime driver fuelling the growth of the market is the rising occurrence of NAFLD cases and their transformation to NASH. In addition, the shifting lifestyle patterns and increasing obesity are also stimulating the growth of the market. However, as mentioned in the report, the nonalcoholic steatohepatitis market is presently in its nascent stage owing to the fact that there is an absence of FDA-approved drugs for the treatment of NASH till date. This will have a negative impact on the growth of the market. Nevertheless, there are numerous pipeline drugs in phase II and phase III of clinical trials, including Aramchol and Elafibranor and these can emerge as potential drugs within the market for the treatment of NASH.

The report states that this disease is comparatively less prominent as compared to other disorders of the liver. The progression of NASH takes place over a period of time as a subtle and gradual process. In addition, NASH may either recede or halt without the requirement for any treatment owing to the liver's regenerative property. This may also act as a key barrier for the growth of the market for nonalcoholic steatohepatitis, as per this report.

Brochure Download:

According to the report, the chief players operating in the market for nonalcoholic steatohepatitis are Echosense SA, Exalenz Bioscience Inc., AstraZeneca plc, Galmed Pharmaceuticals Ltd., GENFIT Corp, Intercept Pharmaceuticals, Inc., Galectin Therapeutics Inc., One Way Liver Genomics, Perspectum Diagnostics, S.L, Matinas Biopharma Holdings, Inc., and Vital Therapies, Inc., among others.

Contact us:

Mr. Sudip S

Transparency Market Research

90 State Street,

Suite 700,


NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free 866-552-3453